PRACTICE RECOMMENDATIONS
Terazosin, an alpha-1-adrenergic blocker, is well tolerated, relieves pain symptoms, and improves quality of life in healthy men aged 20 to 50 years who have chronic prostatitis/chronic pelvic pain syndrome.
Terazosin should be strongly considered as a first-line treatment in such patients. However, men with infectious prostatitis were excluded from this study. Also, the benefits of terazosin beyond 14 weeks are unknown.